Golimumab

• IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WIT… Pending
  2024-517314-15-00 Phase III/IV 1 country Centre Hospitalier Universitaire Amiens Picardie
• Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized cli… Recruiting
  2024-514732-24-00 Phase IV 7 countries IRCCS Istituto Giannina Gaslini
• MOVE-JIA trial Recruiting
  2024-513017-12-00 Phase IV 1 country Oslo University Hospital HF
• Effect of Tofacitinib on coagulation and platelet function, and its role in thromboembolic events Recruiting
  2024-518434-83-01 Phase IV 1 country Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Princesa
• An unblinded clinical Trial with random assignment to Treatment Groups in adult patients with psoriatic arthrits to evaluate how far immunos… Recruiting
  2023-508251-39-00 Phase III 2 countries Universitaetsklinikum Erlangen AöR
• RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASAL… Recruiting
  2024-516704-41-00 Phase III/IV 1 country Les Hopitaux Universitaires De Strasbourg
• Comparing the effectiveness of our tailor-made management approach with routine care from a clinical, patient's as well as an economic point… Ended
  2024-511530-12-01 Phase IV 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended
  2023-504741-32-00 Phase II 19 countries Janssen - Cilag International
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit… Ended
  2023-504743-13-00 Phase II 20 countries Janssen - Cilag International
• SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic prof… Ended
  2023-510085-27-00 Phase III 1 country Universitair Ziekenhuis Gent
• A Study of the Efficacy and Safety of Golimumab in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-507142-83-00 Phase III 3 countries Janssen - Cilag International; Janssen Biologics B.V.

Showing 1–11 of 11 trials